AbbVie rolls up another big win for elagolix as the prospective blockbuster sweeps endpoints in latest PhIII
Already on the fast priority track at the FDA with their application to start selling elagolix for endometriosis, AbbVie $ABBV said today that the drug also came through with flying colors in the first of two pivotal trials for uterine fibroids.
This drug has already been tapped as a likely blockbuster for AbbVie, one of several top drugs in its late-stage pipeline as the company looks to add to a commercial portfolio dominated by Humira.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.